- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02245009
Safety of External Electrocardioversion in Device Patients (SEED)
Safety of External Electrocardioversion in Device Patients - the SEED Registry
Arrhythmias of the atria of the heart are a common comorbidity in patients with cardiac rhythm management devices, such as pacemakers and implantable cardioverter/defibrillators (ICD). External electrical cardioversion is an established method to achieve rhythm control (restore normal sinus rhythm) in patients with atrial arrhythmia. Little data on safety and efficacy of external electrical cardioversion in patients with cardiac rhythm management devices exists. Thus, available data on the safety of external electrical cardioversion in cardiac rhythm management patients lacks statistical power to accurately reflect the true hazard of external electrical cardioversion in patients with cardiac rhythm management devices.
The aim is to systematically include and follow all patients with cardiac rhythm management devices presenting for external electrical cardioversion, to analyse the effects of external electrical cardioversion on leads and devices.
Studieoversikt
Detaljert beskrivelse
Introduction Atrial arrhythmias are a common comorbidity in patients with cardiac rhythm management (CRM) devices, such as pacemakers and ICD. External electrical cardioversion is an established method to achieve rhythm control in patients with atrial arrhythmia. A paucity of data on safety and efficacy of external electrical cardioversion in patients with cardiac rhythm management devices exists. Most publications are of older date and predominantly case reports or case collections. Few prospective studies with a population of cardiac rhythm management patients after external electrical cardioversion have been published in recent years.
Thus, available data on the safety of external electrical cardioversion in cardiac rhythm management patients lacks statistical power to accurately reflect the true hazard of external electrical cardioversion in patients with cardiac rhythm management devices.
Rationale Electrocardioversion in Propofol sedation for atrial or ventricular tachyarrhythmia is an established therapy. It is routinely used for patients with cardiac rhythm management devices and the risk of device and lead affectation is deemed to be low. This assumption is currently not supported by substantial and current scientific data, mostly relying on older reports. No large, prospective trials with a population of patients with modern cardiac rhythm management devices exists.
Aim of the study The aim is to systematically include and follow all patients with cardiac rhythm management devices presenting for external electrical cardioversion, to analyse the effects of external electrical cardioversion on leads and devices. Thereby, providing reliable evidence and detecting possible SAE with a low incidence. Furthermore, to gather information on efficacy and recurrence rate in this population, to examine the value of external electrical cardioversion for rhythm control in these patients.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiekontakt
- Navn: Jakob Lüker, Dr.
- Telefonnummer: 32396 +49221478
- E-post: jakob.lueker@uk-koeln.de
Studiesteder
-
-
-
Cologne, Tyskland, 50937
- Rekruttering
- University Hospital Cologne
-
Ta kontakt med:
- Daniel Steven, Prof. Dr.
- Telefonnummer: 32396 +49221478
- E-post: daniel.steven@uk-koeln.de
-
Hovedetterforsker:
- Jakob Lüker, Dr.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years
- Informed, written consent
- Atrial or ventricular arrhythmia with indication for CV
- Status post CRM implantation, including CRT-D
Exclusion Criteria:
- Age < 18 years
- Patients under guardianship or with mental disorders / disabilities
- lead implantation < 4 weeks prior to CV
- contraindications for eCV or transoesophageal echocardiographie (TOE)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Potensielle
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
Pacemaker patients
Patients with pacemaker, presenting for cardioversion.
|
|
ICD patients
Patients with ICD, presenting for cardioversion.
|
|
CRT patients
Patients with CRT device, presenting for cardioversion.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Composite safety endpoint: Changes of lead and device parameters
Tidsramme: 2 weeks after CV
|
assessed by device interrogation, if any of the following criteria is met:
|
2 weeks after CV
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Efficacy Endpoint
Tidsramme: within 15 minutes after CV
|
Assessed by device interrogation and 12-lead ECG: - restoration of normal sinus rhythm after CV |
within 15 minutes after CV
|
Late changes of lead parameters
Tidsramme: 2 weeks after CV
|
Any of the below, assessed by device interrogation:
|
2 weeks after CV
|
Inadvertent induction of ventricular fibrillation
Tidsramme: 10 seconds after CV
|
Assessed by 3 lead monitoring ECG
|
10 seconds after CV
|
Composite endpoint: Early lead changes
Tidsramme: within 15 minutes after CV
|
assessed by device interrogation, if any of the following criteria is met:
|
within 15 minutes after CV
|
Loss of programming
Tidsramme: within 15 minutes after CV
|
assessed by device interrogation: - loss of programming of the device |
within 15 minutes after CV
|
Change of shock impedance
Tidsramme: within 15 minutes after CV
|
assessed by device interrogation: - rise in shock impedance by 50% |
within 15 minutes after CV
|
Change of charge time
Tidsramme: within 15 minutes after CV
|
assessed by device interrogation: - rise in charge time by 50% |
within 15 minutes after CV
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Jakob Lüker, Dr., University Hospital Cologne
- Studieleder: Daniel Steven, Prof. Dr., University Hospital Cologne
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- UKK-SEED-2014
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Atriearytmi
-
Pusan National University HospitalHar ikke rekruttert ennåHjerteimplanterbar elektronisk enhet | Atrial High Rate EpisodeKorea, Republikken
-
The Second Affiliated Hospital of Chongqing Medical...UkjentAtrieflimmer | Hjerteombygging, atrial | Sacubitril/Valsartan
-
W.L.Gore & AssociatesFullført
-
Helios Klinikum PforzheimRekrutteringHøyre hjertesvikt | Trikuspidal regurgitasjon | Hjerteombygging, Ventrikulær | Hjerteombygging, atrialTyskland
-
Henry Ford Health SystemTilbaketrukket
-
Nobles Medical Technologies II IncPåmelding etter invitasjonForamen Ovale, patent | Septal defekt, atrial | Septaldefekt, hjerteForente stater, Italia
-
HeartStitch.ComUkjentForamen Ovale, patent | Septal defekt, atrial | Septaldefekt, hjerteForente stater
-
China National Center for Cardiovascular DiseasesRekrutteringHjertesykdommer | Atrial septal dilatasjonKina
-
Assiut UniversityUkjent
-
Amsterdam UMC, location VUmcRekruttering
Kliniske studier på Cardioversion
-
Our Lady of the Lake Regional Medical CenterUkjentSepsis | Respirasjonssvikt | Nyoppstått atrieflimmerForente stater